Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07283822 · ClinicalTrials.gov registry record · Phase 2
Amping up With PemJAK
A Phase 2 study of Non-Hodgkin Lymphoma and Peripheral T-Cell Lymphoma, sponsored by Seda S. Tolu.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 1
- Study location
NCT07283822 is a Phase 2 study of Non-Hodgkin Lymphoma and Peripheral T-Cell Lymphoma that is actively recruiting participants, run by Seda S. Tolu. The registered enrollment target is 53 participants, below the 151-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07283822, a Phase 2 study of Non-Hodgkin Lymphoma and Peripheral T-Cell Lymphoma, is actively recruiting participants, sponsored by Seda S. Tolu.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Ruxolitinib
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2025-12-03 |
| Est. Completion | 2029-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07283822
The ClinicalTrials.gov registry entry for NCT07283822 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 151-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (65% lower). The listed sponsor is Seda S. Tolu, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT07283822 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07283822 about?
NCT07283822 is a clinical study titled "Amping up With PemJAK". The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.
What is the current status of trial NCT07283822?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2025-12-03. Estimated completion is 2029-01.
What conditions does trial NCT07283822 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma, Non-Hodgkin Lymphoma Refractory/ Relapsed, Hodgkin Disease Recurrent.
What interventions are being tested in trial NCT07283822?
The interventions under investigation include: Pembrolizumab (DRUG), Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT07283822?
This trial is sponsored by Seda S. Tolu, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07283822 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
RECRUITING · Phase 2
-
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RECRUITING · Phase 2
-
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
RECRUITING · Phase 2
-
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
RECRUITING · Phase 2
-
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RECRUITING · Phase 2
-
Epco, Zanu, Ritux for R/R FL or MZL
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.